Elsevier

Autoimmunity Reviews

Volume 2, Issue 3, May 2003, Pages 152-157
Autoimmunity Reviews

New insights into the pathogenesis of systemic sclerosis

https://doi.org/10.1016/S1568-9972(03)00004-1Get rights and content

Abstract

Systemic sclerosis (SSc) is a connective tissue disorder characterized by vascular abnormalities and excessive collagen synthesis. Extracellular matrix overproduction by fibroblasts results from abnormal interactions among endothelial cells, mononuclear cells (lymphocytes and monocytes) and fibroblasts, in a setting of vascular hyperreactivity and tissue hypoxia. Many autoantibodies have been identified in the sera of SSc patients; some of them are specific to the disease, such as anti-centromere antibodies in limited SSc, anti-topoisomerase 1 and anti-RNA polymerase I/III antibodies in diffuse SSc. Their pathogenetic role(s) remains uncertain. However, genetic, environmental and possibly alloreactive factors might also contribute to disease susceptibility.

Introduction

Systemic sclerosis (SSc) is characterized by skin and visceral fibrosis, and vascular abnormalities including Raynaud's phenomenon, pulmonary arterial hypertension (PAH) and renal crisis [1]. Extracellular matrix overproduction by fibroblasts is the hallmark of SSc. Collagen accumulation results from abnormal interactions among endothelial cells (EC), mononuclear cells (lymphocytes and monocytes) and fibroblasts leading to the production of fibrosis-inducing cytokines, in a setting of vascular hyperreactivity and tissue hypoxia (Fig. 1) [2]. Numerous autoantibodies have been identified in the serum of SSc patients, but their pathogenetic role(s) remains uncertain. Finally, alloreactivity, together with genetic and environmental factors could contribute to disease susceptibility.

Section snippets

Cells and cytokines involved in the pathogenesis of SSc

SSc fibroblasts are activated and overproduce extracellular matrix proteins, such as collagens I, III, V, VI and VII, tenascin, proteoglycans, fibronectin, laminin and fibrillin-1 [3]. Myofibroblasts which can differentiate from fibroblasts in the presence of thrombin are mainly responsible for increased collagen production [4]. Collagen synthesis is dependent on transforming growth factor-beta (TGF-β) a cytokine produced by fibroblasts and EC, and on connective tissue growth factor (CTGF),

Autoantibodies

Autoantibodies to cellular components are detected in most SSc patients. Three of these autoantibodies are disease-specific and mutually exclusive; anti-centromere Ab (ACA), anti-topoisomerase 1 Ab (ATA) and anti-RNA polymerase (RNAP) III Ab. Other autoantibodies have been identified in SSc patients, directed against nucleolar, cytoplasm, membrane structures, extracellular matrix components, fibroblasts and/or EC.

Microchimerism

Several studies have shown an association between the development of SSc in women sometimes after pregnancy and the detection of fetal cells in peripheral blood [36], [37]. These results led to the hypothesis that SSc may be the consequence of an allogeneic fetomaternal reaction that might be a manifestation of an intergenerational HLA incompatibility [36], [37]. However, certain normal female controls also exhibit microchimerism, and its role in SSc remains unproven, but it probably

Genetic and environmental factors

With insufficient evidence supporting an environmental cause, recent attention has focused on the role of genetic factors in the occurrence of SSc. Thus, a positive family history is the strongest risk factor yet identified for SSc [38]. Human leukocyte antigen associations exist but more closely reflect the presence of particular autoantibodies than SSc and no single major histocompatibility complex allele predisposes to SSc in all ethnic groups. The fibrillin-1 gene, that is partially

Acknowledgements

This work was supported by the Association des Sclérodermiques de France and INSERM (CReS No. 4CR08F). Y. Chanseaud was funded by the Ministère de l'Enseignement Supérieur et de la Recherche, France.

References (40)

  • A. Leask et al.

    Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis

    Curr Rheumatol Rep

    (2002)
  • C. Dong et al.

    Deficient Smad7 expression: a putative molecular defect in scleroderma

    Proc Natl Acad Sci USA

    (2002)
  • A. Leask et al.

    Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts

    Arthritis Rheum

    (2002)
  • A. Leask et al.

    The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts

    Mol Pathol

    (2001)
  • O. Distler et al.

    Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis

    Arthritis Rheum

    (2001)
  • S. Akimoto et al.

    Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation

    Br J Dermatol

    (1998)
  • T. Yamamoto et al.

    Expression of stem cell factor in the lesional skin of systemic sclerosis

    Dermatology

    (1998)
  • L.I. Sakkas et al.

    Oligoclonal T cell expansion in the skin of patients with systemic sclerosis

    J Immunol

    (2002)
  • S.P. Atamas et al.

    Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis

    Arthritis Rheum

    (1999)
  • S. Majumdar et al.

    Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies

    Eur Respir J

    (1999)
  • Cited by (0)

    View full text